Analyst Price Targets — ARWR
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| September 24, 2026 8:47 am | Andrea Newkirk | Goldman Sachs | $74.00 | $66.96 | TheFly | Arrowhead resumed with a Neutral at Goldman Sachs |
| August 31, 2026 12:40 pm | Luca Issi | RBC Capital | $100.00 | $82.32 | StreetInsider | RBC Capital Reiterates Outperform Rating on Arrowhead Pharma (ARWR) |
| August 6, 2026 4:13 pm | — | H.C. Wainwright | $120.00 | $85.61 | TheFly | Arrowhead price target raised to $120 from $115 at H.C. Wainwright |
| August 5, 2026 11:05 am | — | Stifel Nicolaus | $104.00 | $89.59 | TheFly | Arrowhead price target raised to $104 from $98 at Stifel |
| July 27, 2026 10:02 am | — | H.C. Wainwright | $115.00 | $85.60 | TheFly | Arrowhead price target raised to $115 from $100 at H.C. Wainwright |
| July 23, 2026 12:43 pm | — | Morgan Stanley | $120.00 | $88.38 | TheFly | Arrowhead price target raised to $120 from $100 at Morgan Stanley |
| July 23, 2026 11:05 am | Edward Tenthoff | Piper Sandler | $126.00 | $88.70 | TheFly | Arrowhead price target raised to $126 from $110 at Piper Sandler |
| July 22, 2026 5:07 pm | Keay Nakae | Chardan Capital | $115.00 | $91.03 | TheFly | Arrowhead price target raised to $115 from $90 at Chardan |
| July 13, 2026 8:11 pm | James Condulis | Stifel Nicolaus | $98.00 | $74.11 | TheFly | Arrowhead initiated with a Buy at Stifel |
| May 13, 2026 10:27 am | — | Bernstein | $46.00 | $79.04 | TheFly | Arrowhead price target raised to $46 from $35 at Bernstein |
Latest News for ARWR
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the United States Food and Drug Administration (FDA) has granted plozasiran entry in the Split Real Time Application Review (STAR) pilot program in connection with Arrowhead's upcoming supplemental new drug application (sNDA) for severe hypertriglyceridemia (sHTG). SHTG is a condition that significantly…
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR - Get Free Report) shares crossed below its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $75.86 and traded as low as $62.22. Arrowhead Pharmaceuticals shares last traded at $62.35, with a volume of 2,249,374 shares traded. Analyst Upgrades and Downgrades Several research firms
Arrowhead Pharmaceuticals is positioned to challenge Ionis in severe hypertriglyceridemia (sHTG) with plozasiran, leveraging a faster launch via a $215M priority review voucher. ARWR's SHASTA-3 and SHASTA-4 Phase III data show plozasiran achieves 79–81% median triglyceride reductions and favorable safety, with quarterly dosing and no liver fat or thrombocytopenia signals. Current financials reflect partner-driven…
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced its plan to host an R&D webinar on Wednesday, October 14, 2026, at 11:30 AM PDT that will focus on investigational therapy ARO-MAPT and Arrowhead's central nervous system (CNS) pipeline. The webinar will feature a presentation from Adam Boxer, M.D., Ph.D., Endowed Professor in Memory and Aging in the…
Arrowhead Pharmaceuticals NASDAQ: ARWR executives outlined early clinical data for its RNA interference dimer program, progress in the launch of plozasiran and plans for central nervous system and metabolic disease candidates during the Morgan Stanley Global Healthcare Conference. Get ARWR alerts:Sign UpEarly Dimer Data Points to Dual-Target Approach Chief Executive Officer Chris Anzalone said the company's…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ARWR.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.